Appointment of BSR & Co.LLP Chartered Accountants as the Statutory Auditors of the Company.
ONESOURCE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
OneSource Specialty Pharma has announced two key outcomes from its May 13, 2026 board meeting. First, the company reported audited standalone and consolidated financial results for Q4 and FY2026 ended March 31, 2026, with Deloitte Haskins & Sells providing an unmodified (clean) opinion on both sets of results. Second, the board approved the appointment of BSR & Co. LLP as the new statutory auditors for a 5-year term from the conclusion of the 19th AGM until the 24th AGM, replacing Deloitte Haskins & Sells whose term is completing as per statutory rotation requirements. BSR & Co. LLP is a large LLP firm with 170 partners and over 4,000 personnel across 14 Indian locations, serving multiple listed companies including pharma sector clients.
The auditor change from a Big 4 firm (Deloitte) to BSR & Co. LLP (member of BSR & Affiliates network) represents routine statutory rotation compliance and is unlikely to have any negative impact on the stock. The clean audit opinions indicate satisfactory financial reporting quality. Shareholders should note the change will be effective subject to shareholder approval at the ensuing AGM.